Hepatitis C News and Research

Latest Hepatitis C News and Research

Researchers find ways to identify, isolate HCC progenitor cells before tumors become evident

For the first time, researchers at the University of California, San Diego School of Medicine have isolated and characterized the progenitor cells that eventually give rise to malignant hepatocellular carcinoma tumors - the most common form of liver cancer. The researchers found ways to identify and isolate the HCC progenitor cells long before actual tumors were apparent.

11 Oct 2013

Adding danoprevir to treatment regimen for hepatitis C patients leads to high rates of remission

The addition of danoprevir to the current treatment regimen for patients with hepatitis C leads to high rates of remission, according to a new article in Gastroenterology, the official journal of the American Gastroenterological Association.

11 Oct 2013

Patients who received care at multiple HIV clinics have higher HIV viral loads

Patients who received care at multiple HIV clinics—as opposed to only one— were less likely to take their medication and had higher HIV viral loads, a new study published in the journal AIDS and Behavior of almost 13,000 HIV patients in Philadelphia from Penn Medicine found.

10 Oct 2013

Receiving care at several HIV clinics may increase medication errors

Patients who received care at multiple HIV clinics-as opposed to only one- were less likely to take their medication and had higher HIV viral loads, a new study published in the journal AIDS and Behavior of almost 13,000 HIV patients in Philadelphia from Penn Medicine found.

10 Oct 2013

Research on flaviviruses could help in developing effective therapies for persistent infections

We generally do not devote much time to worrying about the problems faced by viruses, although understanding them may provide clues on how to combat diseases.

9 Oct 2013

Researchers recently launched Collaborative Hepatitis Network in Africa

Although it does not receive as much attention as AIDS, hepatitis has long been one of Africa's most serious health problems.

9 Oct 2013

Healthcare providers report unaccompanied teens may not receive required vaccines

Healthcare providers report that older teens often go to the doctor without a parent or guardian, a new survey in the Journal of Adolescent Health reveals—and those teens may not get necessary vaccinations because there's no parent or guardian present to give consent.

9 Oct 2013

Janssen buys all rights from GSK to develop, commercialize hepatitis C compound

Janssen Pharmaceuticals, Inc. announced today the acquisition of the investigational compound GSK2336805, an NS5a replication complex inhibitor in Phase 2 development for the treatment of chronic hepatitis C, from an affiliate of GlaxoSmithKline plc.

9 Oct 2013

Sahlgrenska Academy study finds no traces of viruses in breast cancer and glioblastoma

A major study conducted at the Sahlgrenska Academy has now disproved theories of a viral cause for breast cancer and the brain tumour, glioblastoma. The study, which was based on over seven billion DNA sequences and which is published in Nature Communications, found no genetic traces of viruses in these forms of cancer.

9 Oct 2013

Arrowhead initiates Phase 1 study of ARC-520 for treatment against chronic HBV infection

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it completed enrollment in a Phase 1 clinical trial of ARC-520, its RNAi-based candidate against chronic hepatitis B virus infection.

9 Oct 2013

Boehringer Ingelheim’s interim data from Phase II HCV clinical collaboration with Presidio Pharmaceuticals accepted for presentation at AASLD

Boehringer Ingelheim today announced that interim data from its Phase II hepatitis C (HCV) clinical collaboration with Presidio Pharmaceuticals have been accepted for presentation as a late breaker poster at the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), taking place 1-5 November in Washington, D.C. (1) The poster presentation will be on Monday 4 November.

8 Oct 2013

J&J's Janssen Buys Rights To Hepatitis C Compound From GSK

...

8 Oct 2013

Vaccination campaign led HBV to more than double rate of "breakout" mutations

A universal infant vaccination campaign in China has led the Hepatitis B virus (HBV) to more than double its rate of "breakout" mutations. These mutations may enable the virus to elude the vaccine, necessitating new vaccination strategies.

8 Oct 2013

New injection device delivers optimum treatment dose to hepatitis C patients

A new injection device, ViraferonPeg Clearclick, has launched in the UK today for hepatitis C patients to accurately titrate and self-administer their weekly dose of ViraferonPeg (peginterferon alfa-2b).

5 Oct 2013

Saint Luke's liver transplantation program receives CMS certification

The liver transplantation program at Saint Luke's Hospital of Kansas City has received certification by the Centers for Medicare and Medicaid. The certification is an important step in enhancing the hospital's ability to care for Medicare-covered patients suffering from end-stage liver disease, and attract other insurers who base their coverage on the CMS certification.

2 Oct 2013

Researchers develop renal risk index to predict post-transplant end-stage renal disease

End-stage renal disease is one of the major public health problems among solid organ transplant recipients that is associated with death after transplant and high cost of care.

2 Oct 2013

Data from Boehringer Ingelheim's HCV clinical program accepted for presentation at The Liver Meeting

New data from Boehringer Ingelheim's hepatitis C virus clinical development program have been accepted for presentation at the 64th Annual Meeting of the American Association for the Study of Liver Diseases, also known as The Liver Meeting®, taking place November 1-5 in Washington, D.C.

1 Oct 2013

Merck & Co. Axes 8,500 In R&D Restructuring

...

1 Oct 2013

Merck & Co. Axes 8,500 In R&D Restructuring

...

1 Oct 2013

Canada should start screening 'Baby Boomers' for hepatitis C virus infection, say liver specialists

Canada should begin screening 'Baby Boomers' for the hepatitis C virus infection, since this age group is likely the largest group to have the illness, and most don't know they have it, say a group of liver specialists in the Toronto Western Hospital Francis Family Liver Clinic. Unlike many other chronic viral infections, early treatment makes hepatitis C curable.

1 Oct 2013

Hepatitis C News and Research

Latest Hepatitis C News and Research

Researchers find ways to identify, isolate HCC progenitor cells before tumors become evident

Adding danoprevir to treatment regimen for hepatitis C patients leads to high rates of remission

Patients who received care at multiple HIV clinics have higher HIV viral loads

Receiving care at several HIV clinics may increase medication errors

Research on flaviviruses could help in developing effective therapies for persistent infections

Researchers recently launched Collaborative Hepatitis Network in Africa

Healthcare providers report unaccompanied teens may not receive required vaccines

Janssen buys all rights from GSK to develop, commercialize hepatitis C compound

Sahlgrenska Academy study finds no traces of viruses in breast cancer and glioblastoma

Arrowhead initiates Phase 1 study of ARC-520 for treatment against chronic HBV infection

Boehringer Ingelheim’s interim data from Phase II HCV clinical collaboration with Presidio Pharmaceuticals accepted for presentation at AASLD

J&J's Janssen Buys Rights To Hepatitis C Compound From GSK

Vaccination campaign led HBV to more than double rate of "breakout" mutations

New injection device delivers optimum treatment dose to hepatitis C patients

Saint Luke's liver transplantation program receives CMS certification

Researchers develop renal risk index to predict post-transplant end-stage renal disease

Data from Boehringer Ingelheim's HCV clinical program accepted for presentation at The Liver Meeting

Merck & Co. Axes 8,500 In R&D Restructuring

Merck & Co. Axes 8,500 In R&D Restructuring

Canada should start screening 'Baby Boomers' for hepatitis C virus infection, say liver specialists

Innovation in neuroscience drug discovery - eBook eBook

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Hepatitis C News and Research

Latest Hepatitis C News and Research

Innovation in neuroscience drug discovery - eBook eBook

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Newsletters you may be interested in